Alembic Pharma wins USFDA approval for generic ear infection drug
In short
Alembic Pharmaceuticals said on Monday that the US FDA gave final approval for its generic ear infection medicine. The drug is for certain ear infections in babies aged six months and older, adults and older people, and it matches Sandoz’s reference product.
This matters because the approval can help Alembic sell the medicine in the US market. The report does not say when sales will start or how much money it could bring in.
What the reporting says
Alembic Pharmaceuticals said on Monday it received final USFDA approval for its generic Ciprofloxacin and Dexamethasone Otic Suspension USP. The product is indicated for certain ear infections in pediatric patients aged six months and older, as well as adults and elderly patients, and the company said it is therapeutically equivalent to Sandoz’s reference drug Ciprodex Otic Suspension. The reporting does not state when sales will begin or the financial impact.
Why it matters
Alembic Pharmaceuticals said it received final USFDA approval on Monday for generic Ciprofloxacin and Dexamethasone Otic Suspension USP, according to the report. The drug is for certain ear infections in pediatric patients aged six months and older, plus adults and elderly patients, and is therapeutically equivalent to Sandoz’s Ciprodex Otic Suspension. The reporting does not state launch timing or commercial impact, so the near-term effect is regulatory clearance rather than confirmed sales.